Grants and Contributions:
Title:
COVID-19 Test Development
Agreement Number:
947397
Agreement Value:
$687,928.00
Agreement Date:
Mar 23, 2020 - Dec 31, 2020
Description:
Spartan Bioscience (Spartan) proposes development of a SARS-CoV-2 assay to operate on its Cube sample-to-result real-time PCR testing platform. The proposed assay will have a simple workflow requiring no sample preparation after sample collection. The portable size of the Cube, along with the simplicity of the proposed workflow allows the solution to be deployed and implemented into airports, border crossings, and critical national infrastructure with ease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Ottawa, Ontario, CA K2H 1B2
Reference Number:
172-2019-2020-Q4-947397
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
855952438
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Nov 27, 2020
Recipient's Legal Name:
Spartan Bioscience Inc.
Federal Riding Name:
Ottawa West--Nepean
Federal Riding Number:
35079
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
334512
Amendments: